Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Using a "dose-dense" regimen of paclitaxel and carboplatin in heavily pre-treated, platinum- resistant ovarian cancer patients, a UK oncology group demonstrated that a more protracted treatment schedule (six months) was both tolerable and associated with an impressive overall response rate (60%). The findings provide rationale for a randomized clinical trial to examine this approach for relapsed ovarian cancer, particularly for those who relapse within a year of completing initial platinum-based treatment.

Weekly Dose-dense Paclitaxel-Carboplatin for Recurrent Ovarian Cancer